P115 BONE ALKALINE PHOSPHATASE (BAP) ASSAY VALIDATION USING EQUINE SERUM AND SYNOVIAL FLUID  by Trumble, T.N. et al.
Osteoarthritis and Cartilage Vol. 14, Supplement B S73
Conclusions: These results indicate that pentosidine may play
an important role in the process of pathophysiology of chronic
rheumatic diseases and DM complications.
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Purpose: Bone undergoes reformation in response to the de-
mands placed upon it. Examination of both the serum and
synovial fluid BAP concentrations in joint disease may be valu-
able in determining the different local and systemic effects that
occur to bone in response to exercise and injury. BAP has been
shown to be a good biomarker for early osteoblastic activity
when joint injury is present. The investigators have performed
previous studies demonstrating the capability of the commercially
developed Metra® BAP ELISA to determine differences in bio-
logical activity of equine serum and synovial fluid (SF) samples.
BAP is well conserved across species, and the Quidel Corpo-
ration has demonstrated species cross reactivity with the horse.
Thus, because the horse is a good translational model of OA for
biomarker evaluation, the objective of this study was to validate
the use of equine serum and SF with the Metra® BAP ELISA.
Fig. 1. Specificity was examined for serum (A) and SF (B) by mixing together the high, medium and low quality control samples (mQC). This mixture was serially
diluted at 1:2, 1:4, 1:8, and 1:10. The results of this serial dilution were then compared to the standard curve that was derived using the standards provided by the
manufacturer by comparing the absorbance to the concentration. The samples demonstrated parallelism to the master standard curve.
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Fig. 2. Linearity of dilution was analyzed in serum (A) and SF (B) by serially diluting QC samples (high, medium, and low) at the following dilutions: 1:2, 1:4, 1:8, and
1:10. The concentration of each dilution was determined from the standard curve and the observed concentration was plotted against the reciprocal of the dilution
(1/dilution).
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Methods: Metra® BAP ELISAs (Quidel Corporation) were used
for this validation study according to manufacturer protocols.
Internal quality control (QC) samples were prepared using the
highest concentration standard provided by the manufacturer
(140 U/L). To create QC samples, fresh serum was collected
from 3 normal horses and fresh SF was collected aseptically
from 12 middle carpal and 12 radiocarpal joints from 6 normal
horses. The samples were respectively pooled together for fur-
ther processing and analysis. Each group of pooled samples
were spiked with a known amount of standard to create samples
with high, medium and low levels of BAP. The QC samples were
used to determine the precision, specificity, sensitivity, accuracy,
linearity of dilution, and stability of this assay with equine serum
and SF.
Results: The standard optical density (OD) values exhibited ac-
ceptable reproducibility of the standard curve over 10 plates with
an overall inter-assay precision mean coefficient of variation (CV)
of 8.1% (range; 4.9-12.3%). Serum and SF samples exhibited ac-
ceptable intra-assay and inter-assay precision over 3 plates with
an overall mean CV of 3.3% (range; 0.1-8.1%) and 7.2% (range;
5.7-9.6%), respectively for the serum, and 2.6% (range; 0.2-
7.5%) and 7.1% (range; 4.8-8.8%), respectively for the SF. Paral-
lelism of serum and SF sample dilutions (1:2, 1:4, 1:8, and 1:10)
was demonstrated when compared to the standard curve (Fig. 1).
Lowest detection limit of the assay was determined to be 1.6
U/L. Percent recovery for serum was 103.1% for high, 111.6%
for medium, and 116.1% for low QC samples. Percent recovery
for SF was 64.8% for high, 86.1% for medium, and 91.2% for low
QC samples. Linearity of serum and SF sample dilutions (1:2,
1:4, 1:8, and 1:10), was demonstrated (Fig. 2). The results also
demonstrated that no more than 2 freeze/thaw cycles should be
S74 Poster Presentations
performed per sample for the serum, but that there is minimal
loss of the BAP analyte out to 5 freeze/thaw cycles for the SF.
Conclusions: The Metra® BAP assay is a reproducible and valid
assay for use with equine serum and synovial fluid.
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Purpose: Synovial fluid as a lubricant of knee joints has its vis-
cosity depending on the molecular weight (MW) and concentra-
tion of hyaluronan (HA). HA concentration in synovial fluid have
been frequently reported, but there are few reports analysing
MW of HA in synovial fluid of patients with osteoarthritis(OA).
The purpose of this study was to measure the MW of HA by
using SEC-LALLS (Size-exclusion chromatography(SEC)- a low-
angle laser light scattering(LALLS)) system, and to evaluate the
change in MW of HA after glucosamine administration.
Methods: Five knee OA patients(3 men, 2 women, mean age:
60.6 years) recieved 1.5g of glucosamine hydrochloride per day
for one month. Synovial fluid samples were collected before and
after glucosamine administration.The SEC-LALLS system(Asahi
Techneion) was used to determine the MW of HA. First,the HA
fraction was separated by using SEC system and then the MW of
HA was calculated by measuring LALLS and refractive index(RI).
Triple Detector Array (Viscotek Corporation)which has a LALLS
detector, a RI detector and a viscometer was utilized for the
measurement. Before analyzing HA samples, the accuracy of the
SEC-LALLS system was calibrated with three HA standards (su-
venyl, artz and HA(lowMW-type)(Seikagaku Corporation). (MW
of suvenyl, artz and low MW HA: 1900-2500, 600-1200 and
100-150(kDa)) Furthermore, hyaluronidase treatment was also
done for the confirmation of HA. As a clinical test,visual analogue
scale (VAS) of OA patients was also measured.
Results: The SEC-LALLS system was effective in the MW mea-
surement of HA. MW of three kinds of HA standards,suvenyl,
artz and HA(lowMW-type)were estimated as 2400, 870 and
160(kDa)respectively. It was succeeded that HA fraction was
isolated and identified from synovial fluid samples using this sys-
tem with high sensitivity. As a proof of HA, it was demonstrated
that this peak fraction from HA disappeared after hyaluronidase
digestion. The MW of HA (mean±SD) in synovial fluid of OA pa-
tients increased from 4350±1170 to 5030±1280(kDa) after glu-
cosamine treatment. VAS for knee pain(mean±SD) decreased
significantly from 4.8±1.3 to 1.7±1.0.
Conclusions: We could separate HA from human synovial fluid
and determine the MW of HA with high sensitivity by using
the SEC-LALLS system. A change in MW of HA was detected
after glucosamine treatment, and knee pain was also alleviated.
Therefore these changes suggested glucosamine had an effect
on the metabolism of HA. Estimating the change in MW of
HA by this system may be useful for monitoring a treatment
process of symptom modifying OA drugs. Nevertheless, further
clinical studies in a lager scale are needed to investigate the
improvements in clinical symptoms with alterations in MW of HA
in synovial fluid.
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Purpose: The expression of chondrogenic markers (collagen
type II and X, aggrecan, cartilage oligomeric matrix protein)
are largely restricted to cartilage and play a role in cartilage
metabolism and function. Recently we have shown that (unpub-
lished) these markers are also expressed in adult rat bone and
primary osteoblasts. In this study, we sought to confirm their
expression at mRNA and protein level in bone; compare the
temporal expression of these markers to established osteogenic
markers in ovariectomized (Ovx) rat model of osteopenia; and
evaluate the regulation of these markers upon treatment with
known bone anabolic agents.
Methods: Six-month old, female Sprague Dawley rats (n=10),
were Ovx or sham-operated. The animals were sacrificed at 2,
4, 6, 8 and 12 weeks post-ovx and left femur was analyzed
for BMD and BMC using quantitative computerized tomography.
The right femur (distal metaphysis without epiphysis) was pro-
cessed for mRNA analysis of osteogenic (collagen α1 (I), α2
(I), α1 (V), osteocalcin, osteonectin, bone sialoprotein, biglycan,
alphos) and chondrogenic (collagen α1 (II), aggrecan, COMP,
Cdrap) markers by quantitative real-time PCR (qPCR). Biochem-
ical markers of bone and cartilage turnover (collagen type I and
II degradation products in the serum CTX-I and CTX-II) were
measured by ELISA. Type II collagen and aggrecan proteins
in bones were confirmed by Western analysis and LC/MS. To
assess the effects of bone anabolic agents on the regulation
of bone and cartilage markers, Ovx rats permitted to lose bone
for one month were treated with PTH (1-38) at 10 μg/kg, sc
or 603281-31-8 at 3mg/kg/d (GSK-3 inhibitor), po for 60 days.
Twenty-four hr after the last treatment, RNA from distal femur
metaphysis was analyzed by qPCR to assess the expression
levels of these marker genes. Pearson correlation coefficients
were used to measure correlations between gene expression
and phenotypic parameters
Results: qPCR confirmed the expression of the chondrogenic
markers in bone and in primary osteoblasts. LC/MS and Western
analysis validated the presence of type II collagen and aggrecan
proteins in both metaphyseal and diaphyseal bone. Ovx for 12
weeks resulted in significantly lower BMD at whole and distal
femur (10-15%) relative to sham controls. This was associated
with a temporal decrease in the expression levels of chondro-
genic markers (2 to 5-fold) with optima observed at 8-12 weeks
post-ovx. In contrast, the expression levels of osteogenic mark-
ers steadily increased with maxima observed at 6 weeks (1.2
to 4-fold) followed by decline below sham levels. The levels of
CTX-I and CTX-II were increased in the serum of Ovx rats and
returned to near sham levels by 12 weeks. The magnitude of
change in CTX-II levels (4.8-fold) was > CTX-I (1.9-fold). Treat-
ment with bone anabolics, PTH or GSK-3 inhibitor restored bone
mass in Ovx rats and was associated with a robust increase in
the gene expression of chondrogenic (1.6 to 4.7-fold) compared
to osteogenic markers (1.1 to 1.8-fold). Interestingly, overall the
chondrogenic markers showed a better correlation (r=0.71) to
BMD & BMC compared to osteogenic markers (r<0.5).
Conclusions: These results demonstrate the presence and the
regulation of chondrogenic markers in rat long bone. This sug-
gests either the continued presence of cartilage in adult rat bone
